Nyrada Inc. (ASX:NYR) has dosed and discharged the first cohort of its Phase I human clinical trial of its lead drug candidate, NYR-BI03, according to a Monday filing with the Australian bourse.
The primary endpoint of the trial is to assess the safety and tolerability of NYR-BI03 in healthy volunteers, when administered as a three-hour intravenous infusion, per the filing.
Six participants received NYR-BI03, while two others received a placebo. Readouts from the trial are expected in the third quarter.
NYR-BI03 is a small molecule, first-in-class neuroprotection, and cardioprotection treatment.
Nyrada's shares were down 2% on market close.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。